US · XENE · BIOTECHNOLOGY
Xenon Pharmaceuticals Inc. (XENE) intrinsic value and stock valuation
$37.04as of 2026-11-21 · Mkt cap 6.22B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Xenon Pharmaceuticals Inc. DCF and intrinsic value
InvestorsCraft values XENE with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from XENE’s statements →
Xenon Pharmaceuticals Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $7.5M | $0.00 | $0.00 | $9.43M | $18.4M |
| Operating income | -$-373.07M | -$-279.3M | -$-214.05M | -$-129.14M | -$-78.99M |
| Net income | -$-345.91M | -$-234.33M | -$-182.39M | -$-125.37M | -$-78.88M |
| EPSd | -$-4.36M | -$-3.01M | -$-2.73M | -$-2.07M | -$-1.81M |
| Operating cash flow | -$-279.12M | -$-181.39M | -$-145.33M | -$-98.43M | -$-69.5M |
| Capital expenditure | -$-800K | -$-3.08M | -$-5.62M | -$-2.89M | -$-2.05M |
| Free cash flow | -$-279.92M | -$-184.46M | -$-150.94M | -$-101.32M | -$-71.55M |
| Total assets | $981.7M | $798.1M | $964.8M | $754.2M | $572M |
| Total debt | $7.94M | $9.02M | $10.9M | $10.4M | $8.26M |
| Net debt | -$-191.22M | -$-133.7M | -$-137.74M | -$-46.81M | -$-167.43M |
| Total equity | $581.8M | $754.9M | $927.9M | $721.5M | $550M |
| Cash and short-term investments | $548.9M | $626.9M | $638.1M | $592.1M | $551.8M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $7.5M | $0.00 | $0.00 | $9.43M | $18.4M |
| Cost of revenue | $2.54M | $2.56M | $167.5M | $0.00 | $0.00 |
| Gross profit | $4.96M | -$-2.56M | -$-167.51M | $9.43M | $18.4M |
| Research and development expenses | $300.9M | $210.4M | $167.5M | $105.8M | $75.5M |
| Selling, general and administrative expenses | $79.6M | $68.9M | $46.5M | $32.8M | $22M |
| Other expenses | -$-2.54M | -$-2.56M | -$-167.51M | $0.00 | $0.00 |
| Operating expenses | $378M | $276.7M | $46.5M | $138.6M | $97.4M |
| Cost and expenses | $380.6M | $279.3M | $214.1M | $138.6M | $97.4M |
| Interest income | $26.8M | $41.9M | $27.6M | $8.71M | $470K |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $2.54M | $2.56M | $3.54M | $1.41M | $910K |
| Ebitda | -$-342.35M | -$-235.86M | -$-210.51M | -$-127.74M | -$-78.09M |
| Operating income | -$-373.07M | -$-279.3M | -$-214.05M | -$-129.14M | -$-78.99M |
| Total other income/expenses, net | $28.2M | $40.9M | $31.4M | $3.89M | $100K |
| Income before tax | -$-344.89M | -$-238.42M | -$-182.69M | -$-125.25M | -$-78.89M |
| Income tax expense | $1.02M | -$-4.09M | -$-290K | $120K | -$-10K |
| Net income | -$-345.91M | -$-234.33M | -$-182.39M | -$-125.37M | -$-78.88M |
| Weighted average shares outstanding | $79.3M | $77.9M | $66.9M | $60.5M | $43.6M |
| Weighted average diluted shares outstanding | $79.3M | $77.9M | $66.9M | $60.5M | $43.6M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $548.9M | $626.9M | $638.1M | $592.1M | $551.8M |
| Net receivables | $1.37M | $1.47M | $870K | $990K | $2.77M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $560.7M | $635.3M | $645M | $600.3M | $559M |
| Property, plant and equipment, net | $15.4M | $18.2M | $18.9M | $16.9M | $12.5M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $37.2M | $127.5M | $292.8M | $128.7M | $0.00 |
| Total non-current assets | $421M | $162.9M | $319.8M | $153.9M | $13M |
| Total assets | $981.7M | $798.1M | $964.8M | $754.2M | $572M |
| Accounts payable | $3.88M | $5.07M | $8.6M | $8.49M | $3.82M |
| Short-term debt | $1.53M | $1.37M | $1.3M | $490K | $600K |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $41.8M | $35.6M | $27.3M | $22.7M | $14.3M |
| Long-term debt | $6.41M | $7.65M | $9.6M | $9.95M | $7.65M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $358.1M | $7.65M | $9.6M | $9.95M | $7.65M |
| Capital lease obligations | $6.41M | $9.02M | $10.9M | $10.4M | $8.26M |
| Total liabilities | $399.9M | $43.2M | $36.9M | $32.7M | $22M |
| Common stock | $1.6B | $1.46B | $1.44B | $1.07B | $783.2M |
| Retained earnings | -$-1.25B | -$-899.47M | -$-665.14M | -$-482.75M | -$-357.37M |
| Accumulated other comprehensive income (loss) | $340K | -$-1.61M | -$-80K | -$-3M | -$-990K |
| Total equity | $581.8M | $754.9M | $927.9M | $721.5M | $550M |
| Total investments | $386.9M | $611.7M | $782.2M | $663.5M | $376.1M |
| Total debt | $7.94M | $9.02M | $10.9M | $10.4M | $8.26M |
| Net debt | -$-191.22M | -$-133.7M | -$-137.74M | -$-46.81M | -$-167.43M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-345.91M | -$-234.33M | -$-182.39M | -$-125.37M | -$-78.88M |
| Depreciation and amortization | $2.54M | $2.56M | $3.54M | $1.62M | $910K |
| Stock-based compensation | $53.7M | $50.7M | $32.4M | $20.4M | $10M |
| Change in working capital | $4.36M | $5.71M | $5.63M | -$-680K | -$-2.65M |
| Accounts receivable | $100K | -$-610K | $130K | $1.76M | -$-460K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | -$-2.97M |
| Accounts payable | $5.51M | $8.53M | $3.93M | $8.06M | $2.97M |
| Net cash provided by operating activities | -$-279.12M | -$-181.39M | -$-145.33M | -$-98.43M | -$-69.5M |
| Investments in property, plant and equipment | -$-800K | -$-3.08M | -$-5.62M | -$-2.89M | -$-2.05M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $296M | -$-144.75M |
| Net cash used for investing activities | $218M | $165M | -$-117.17M | -$-296M | -$-246.77M |
| Common stock issued | $117.1M | $12.1M | $353.5M | $277.8M | $447.3M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $117.1M | $12.1M | $353.5M | $278.5M | $447.5M |
| Net change in cash | $56.5M | -$-5.93M | $91.4M | -$-118.45M | $130.7M |
| Cash at end of period | $199.2M | $142.7M | $148.6M | $57.2M | $175.7M |
| Operating cash flow | -$-279.12M | -$-181.39M | -$-145.33M | -$-98.43M | -$-69.5M |
| Capital expenditure | -$-800K | -$-3.08M | -$-5.62M | -$-2.89M | -$-2.05M |
| Free cash flow | -$-279.92M | -$-184.46M | -$-150.94M | -$-101.32M | -$-71.55M |
Line items
Line items
Line items
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
- CEO
- Ian C. Mortimer
- Employees
- 316
- Beta
- 0.61
Explore
Frequently asked questions
What is the intrinsic value of Xenon Pharmaceuticals Inc. (XENE)?
InvestorsCraft does not currently publish an intrinsic value for XENE. How the IC value is calculated.
Is XENE undervalued?
InvestorsCraft does not publish an undervaluation signal for XENE at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.